PE20150890A1 - POLIPEPTIDOS DERIVADOS DEL TGFß Y SUS USOS - Google Patents

POLIPEPTIDOS DERIVADOS DEL TGFß Y SUS USOS

Info

Publication number
PE20150890A1
PE20150890A1 PE2015000549A PE2015000549A PE20150890A1 PE 20150890 A1 PE20150890 A1 PE 20150890A1 PE 2015000549 A PE2015000549 A PE 2015000549A PE 2015000549 A PE2015000549 A PE 2015000549A PE 20150890 A1 PE20150890 A1 PE 20150890A1
Authority
PE
Peru
Prior art keywords
tgfß
alk5
pharmaceutical compositions
fusion proteins
polypeptides
Prior art date
Application number
PE2015000549A
Other languages
English (en)
Inventor
Osorio Angel De Jesus Corria
Monzon Kalet Leon
Portilla Tania Carmenate
Merino Amaury Pupo
Rodriguez Saumel Perez
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49765213&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20150890(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Publication of PE20150890A1 publication Critical patent/PE20150890A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invencion se relaciona con las ramas de la Biotecnologia y particularmente con polipeptidos mutados de la molecula TGFß cuya secuencia primaria tiene una alta homologia con la secuencia del TGFß humano. Estas muteinas pierden la capacidad de interaccion con ALK5 pero conservan la interaccion con el resto de los receptores que forman parte del complejo receptor (TßRll y TßRlll). Tienen la propiedad de antagonizar la senalizacion de todas las variantes naturales de los ligandos TGFß, dependiente del reclutamiento de ALK5 en el complejo receptor y tienen un efecto inmunomodulador. La invencion se relaciona con composiciones farmaceuticas que comprenden como principio activo los polipeptidos o proteinas de fusion divulgados y con el uso terapeutico de los polipeptidos, proteinas de fusion y composiciones farmaceuticas divulgados dado su efecto modulador del sistema inmune sobre patologias como el cancer, enfermedades asociadas con fibrosis y enfermedades infecciosas cronicas
PE2015000549A 2012-11-09 2013-10-30 POLIPEPTIDOS DERIVADOS DEL TGFß Y SUS USOS PE20150890A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20120158A CU24181B1 (es) 2012-11-09 2012-11-09 POLIPÉPTIDOS DERIVADOS DEL TGFß

Publications (1)

Publication Number Publication Date
PE20150890A1 true PE20150890A1 (es) 2015-06-10

Family

ID=49765213

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015000549A PE20150890A1 (es) 2012-11-09 2013-10-30 POLIPEPTIDOS DERIVADOS DEL TGFß Y SUS USOS

Country Status (28)

Country Link
US (1) US9701730B2 (es)
EP (1) EP2918284B1 (es)
JP (2) JP6298823B2 (es)
KR (1) KR102093494B1 (es)
CN (1) CN104902916B (es)
AR (1) AR093391A1 (es)
AU (1) AU2013344022B2 (es)
BR (1) BR112015010145B1 (es)
CA (1) CA2887455C (es)
CL (1) CL2015001252A1 (es)
CO (1) CO7400865A2 (es)
CU (1) CU24181B1 (es)
EA (1) EA031990B1 (es)
ES (1) ES2857176T3 (es)
HK (1) HK1213781A1 (es)
IL (1) IL238621B (es)
JO (1) JO3502B1 (es)
MX (1) MX366060B (es)
MY (1) MY173078A (es)
NZ (1) NZ707850A (es)
PE (1) PE20150890A1 (es)
PH (1) PH12015500807A1 (es)
SG (1) SG11201502980VA (es)
TN (1) TN2015000129A1 (es)
TW (1) TWI615404B (es)
UA (1) UA115678C2 (es)
WO (1) WO2014071894A1 (es)
ZA (1) ZA201504462B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018094173A1 (en) * 2016-11-18 2018-05-24 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Engineered tgf-beta monomers and their use for inhibiting tgf-beta signaling
PL238850B1 (pl) * 2017-10-19 2021-10-11 Calther Polska Spolka Z Ograniczona Odpowiedzialnoscia Aktywna forma transformującego czynnika wzrostu beta 1 (TGFβ1) do zastosowania w leczeniu pacjentów z glejakami wielopostaciowymi, w przypadku których to glejaków ponad 5% komórek nowotworowych jest EGFRvIII-pozytywna

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1087998A1 (en) * 1998-06-16 2001-04-04 Biogen, Inc. Variant type ii tgf-beta receptor fusion proteins and methods
AU778998B2 (en) 1998-09-22 2004-12-23 University Of Maryland At Baltimore Cystine knot growth factor mutants
US6677432B1 (en) * 1998-10-07 2004-01-13 Stryker Corporation Mutations of the C-terminal portion of TGF-β superfamily proteins
ES2146552B1 (es) * 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
JP2008509888A (ja) * 2004-06-30 2008-04-03 モレキュラー ロジックス，インコーポレイテッド 上皮成長因子受容体アンタゴニストおよび使用方法
US7795389B2 (en) * 2004-09-28 2010-09-14 The Board Of Regents Of The University Of Texas System Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins
US7557181B2 (en) * 2005-01-11 2009-07-07 Molecular Logix, Inc. Pan-HER antagonists and methods of use
GB0724051D0 (en) * 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
AU2011243965A1 (en) * 2010-04-22 2012-12-06 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center High affinity leptins and leptin antagonists

Also Published As

Publication number Publication date
CO7400865A2 (es) 2015-09-30
PH12015500807A1 (en) 2015-06-08
TW201431875A (zh) 2014-08-16
JP6298823B2 (ja) 2018-03-20
CU20120158A7 (es) 2014-06-27
JO3502B1 (ar) 2020-07-05
SG11201502980VA (en) 2015-06-29
IL238621A0 (en) 2015-06-30
NZ707850A (en) 2019-08-30
HK1213781A1 (zh) 2016-07-15
EA031990B1 (ru) 2019-03-29
US9701730B2 (en) 2017-07-11
EP2918284B1 (en) 2021-02-17
US20150284441A1 (en) 2015-10-08
MX2015005875A (es) 2015-09-10
KR102093494B1 (ko) 2020-03-26
ES2857176T3 (es) 2021-09-28
CN104902916B (zh) 2018-04-13
EA201590914A1 (ru) 2015-09-30
JP2018111703A (ja) 2018-07-19
CL2015001252A1 (es) 2015-07-17
TN2015000129A1 (en) 2016-10-03
ZA201504462B (en) 2018-11-28
AU2013344022A1 (en) 2015-05-28
UA115678C2 (uk) 2017-12-11
AR093391A1 (es) 2015-06-03
CU24181B1 (es) 2016-04-25
KR20150083848A (ko) 2015-07-20
AU2013344022B2 (en) 2016-12-15
TWI615404B (zh) 2018-02-21
IL238621B (en) 2019-12-31
JP2015535000A (ja) 2015-12-07
BR112015010145A2 (es) 2017-08-22
MY173078A (en) 2019-12-25
CA2887455A1 (en) 2014-05-15
CN104902916A (zh) 2015-09-09
CA2887455C (en) 2022-05-17
EP2918284A1 (en) 2015-09-16
MX366060B (es) 2019-06-26
BR112015010145B1 (pt) 2022-06-07
JP6608473B2 (ja) 2019-11-20
WO2014071894A1 (es) 2014-05-15

Similar Documents

Publication Publication Date Title
CY1122824T1 (el) Πρωτεϊνες συντηξης και εμβολια συνδυασμου
ECSP12011803A (es) Polipéptidos inmunomoduladores derivados de la il-2 y su uso terapéutico en cáncer y en infecciones crónicas
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
CY1119058T1 (el) Ενωσεις ιμιδαζοπυρρολιδινονης
UY36021A (es) Proteìnas fc multimèricas
EA201891186A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
BR112017025108A2 (pt) compostos seletivos de pyy e usos dos mesmos
BR112016026291A2 (pt) Derivados do ácido borônico e usos terapêuticos dos mesmos
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
BR112015014462A2 (pt) vetorização farmacêutica de uma via de sinalização de dinucleotídeos cíclicos de mamíferos
BR112016029848A2 (pt) proteínas de fusão mic-1 e utilizações das mesmas
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
EA201590931A1 (ru) Гетероциклические замещенные производные 2-амино-хиназолина для лечения вирусных инфекций
BR112015022208A8 (pt) proteínas de fusão que compreendem pdgf e partes de ligação de vegf, e métodos de utilização do mesmo
EA201591164A1 (ru) Вакцины против вируса гриппа и их применение
EA202090547A3 (ru) Макроциклические деаза-оксипурины для лечения вирусных инфекций
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
MX2016003419A (es) Metodos y composiciones para sindrome respiratorio coronavirus de oriente medio (mers-cov) inmunogenico.
IN2014KN03063A (es)
EA201590491A1 (ru) Иммуногенная композиция
CY1119957T1 (el) Θεραπεια νοσηματων με τη χρηση ανοχογονου φαρμακευτικου παρασκευασματος
CR20140475A (es) Agentes terapéuticos para administración subcutánea optimizados
AR095527A1 (es) Formulaciones de polipéptido fc-factor ix
AR090073A1 (es) N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
EA201590860A1 (ru) Варианты гемагглютинина и нейраминидазы вируса свиного гриппа

Legal Events

Date Code Title Description
FD Application declared void or lapsed